Drug intelligence / Profile preview

PL-5028

Development stage: Preclinical
Lead developer: Palatin Technologies
Modality: Peptides
Administration: Ophthalmic

Overview

PL-5028 is a synthetic peptide and a dual agonist of the melanocortin 1 (MC1R) and melanocortin 5 (MC5R) receptors, currently under development by Palatin Technologies. As part of Palatin's melanocortin receptor (MCR) platform, PL-5028 is designed to leverage the body's natural anti-inflammatory and pro-resolving pathways to treat various inflammatory conditions. Its primary focus is on ocular diseases, including dry eye disease and retinal diseases, where it aims to reduce inflammation and promote tissue repair. PL-5028 is considered a next-generation follow-on to Palatin's lead ocular candidate, PL-9643, offering potentially optimized pharmacological properties for specific ophthalmic indications.

Targets

NPR1 (Natriuretic peptide receptor 1)NPR3 (Natriuretic peptide receptor C)

Beyond the preview

Go deeper on PL-5028.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PL-5028.

Explore the full profile